Shorter radiation after thymic tumor surgery may cut side effects
NCT ID NCT07691619
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests a shorter, higher-dose-per-day radiation schedule (hypofractionated radiotherapy) given after complete surgical removal of stage II or III thymic epithelial tumors. The goal is to see if this approach is safe and tolerable, while also checking how well it controls the disease and affects quality of life. About 49 adults aged 18–75 with certain types of thymoma or thymic carcinoma are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hypofractionated radiotherapy
- What this could lead to
- If successful, this could offer a more convenient and potentially safer radiation schedule for people with thymic tumors after surgery.
- What could go wrong
- This is a small, early-phase study with no comparison group, so results may not confirm benefit over standard radiation. Side effects are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Talking therapy shows promise for MG patients with depression in tiny pilot study
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New study aims to uncover hidden clues in myasthenia gravis
- New combo therapy shows promise for rare chest cancer